Table 3.

Association^* between tenofovir disoproxil fumarate (TDF) intake/D:A:D chronic kidney disease risk strata and incidence of chronic kidney disease ^†

TDF/D:A:D Risk Group	Unadjusted OR (95% CI)	Adjusted OR (95% CI)
No TDF
Low‐risk	1.00 (Ref)	1.00 (Ref)
Medium‐risk	4.69 (1.70–12.96)	2.32 (0.72–7.52)
High‐risk	37.56 (17.20–82.02)	19.55 (7.35–52.00)
TDF
Low‐risk	0.42 (0.16–1.11)	0.55 (0.19–1.54)
Medium‐risk	5.37 (2.40–12.01)	3.96 (1.38–11.39)
High‐risk	18.30 (8.42–39.78)	12.84 (4.57–36.07)

CI, confidence interval; D:A:D, Data Collection on Adverse Events of Anti‐HIV Drugs; OR, odds ratio.

^*Pooled logistic regression estimated with generalized estimating equations (first‐order autoregressive correlation structure), adjusted for baseline age (restricted cubic splines), sex, race/ethnicity^†, index calendar year (restricted cubic splines) and regimen, as well as time‐updated alcohol misuse, HIV viral load ≥ 50 copies/mL.

^†386 individuals were excluded from analysis due to missing race/ethnicity information.